Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Silvestri, F
Right arrow Articles by Baccarani, M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Silvestri, F
Right arrow Articles by Baccarani, M
Haematologica, Vol 79, Issue 4, 367-370
Copyright © 1994 by Ferrata Storti Foundation

Case Reports

Development of autoimmune thyroid diseases during long-term treatment of hematological malignancies with alpha-interferons

F Silvestri, L Virgolini, A Mazzolini, F Bertolissi, D Russo, R Fanin, and M Baccarani

Department of Medical and Morphological Research, Udine University School of Medicine, Italy.

In recent years recombinant alpha-interferons (alpha-IFNs) have been widely used in the treatment of several hematological malignancies. Prolonged courses of IFN have been shown to induce autoantibodies and to support the exacerbation or even the development of autoimmune diseases. In this report we describe the development of symptomatic autoimmune thyroid diseases in 4 (7.4%) out of 54 patients in chronic treatment with recombinant alpha-IFNs in our department. Two patients developed a disease resembling Hashimoto's thyroiditis after 17 and 49 months of continuous IFN treatment, while the other two developed a typical Graves' disease after 41 and 52 months of therapy. The mechanism by which IFN induces autoimmune thyroid diseases, the choice of searching for anti-thyroid autoantibodies before starting long-term IFN treatment, the option of discontinuing IFN therapy in the presence of overt thyroid diseases, and the management of these diseases are discussed.


This article has been cited by other articles:


Home page
 JRSMHome page
W. B. Chan, C. C. Chow, and C. S. Cockram
Interferon alpha treatment and endocrine disease
J R Soc Med, October 1, 2003; 96(10): 481 - 485.
[Full Text] [PDF]

Home page
 Int ImmunolHome page
D. Braun, I. Caramalho, and J. Demengeot
IFN-{alpha}/{beta} enhances BCR-dependent B cell responses
Int. Immunol., April 1, 2002; 14(4): 411 - 419.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
F. Monzani, N. Caraccio, A. Casolaro, F. Lombardo, G. Moscato, L. Murri, E. Ferrannini, and G. Meucci
Long-term interferon {beta}-1b therapy for MS: Is routine thyroid assessment always useful?
Neurology, August 22, 2000; 55(4): 549 - 552.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
L. Su and M. David
Inhibition of B Cell Receptor-Mediated Apoptosis by IFN
J. Immunol., June 1, 1999; 162(11): 6317 - 6321.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 1994 by the Ferrata Storti Foundation.